Click on image to view larger version.

Figure 2 Pooled data from the included trials. The angiotensin-converting enzyme inhibitor (ACEI) therapy was associated with a decrease in cardiovascular (CV) death (A), all-cause mortality (B), revascularization (C), and nonfatal myocardial infarction (MI) (D). CAMELOT = Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure Trial; EUROPA = European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Arteries trial; HOPE = Heart Outcomes Prevention Evaluation trial; PART-2 = Prevention of Atherosclerosis With Ramipril Trial; PEACE = Angiotensin-Converting Enzyme Inhibition in Stable Coronary Artery Disease; QUIET = Quinapril Ischemic Event Trial; RR = relative risk.